Search results - 9 results
Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology.
were triaged with dual staining (p16/Ki-67) and/or p16 staining and, if available, with a comparator hrHPV test to detect cervical intraepithelial neoplasia of grade 2 or worse (CIN2 +) or CIN3 +. ...
Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017)- Part 1 with Introduction, Screening and the Pathology of Cervical Dysplasia.
Reviews showed that HPV-based screening offers better protection against invasive cervical cancer compared to cytology-based screening. The authors of this guideline therefore recommend — in accordance with ...
Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
HPV assays with genotyping capability. In VALGENT-3, the clinical and analytical performance of Anyplex II HPV HR detection (Anyplex) was compared to that of the Hybrid Capture 2 HPV DNA test (hc2) and ...
Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
reproducibility and non-inferior clinical accuracy for cervical precancer compared to a standard comparator assay. The international reproducibility criteria are: lower bound of 95% confidence interval of the ...
VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples
aims to compare the clinical sensitivity and specificity of particular hrHPV assay(s) on vaginal self-samples and first-void-urine, collected in agreement with standardized protocols, with hrHPV testing ...
Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework.
HPV68. Clinical accuracy for detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2 +) was compared between INNO-LiPA and Hybrid Capture 2 (HC2), which is a standard comparator test for HPV ...
The implementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines.
were compared with the major points of the EuG. Data on the process, and available performance indicators were drawn from the screening database and other National Health Fund (NHF) systems. Joinpoint ...
Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
relative sensitivity and specificity compared to Hybrid Capture-2 or GP5 +/6+ PCR –enzyme immunoassay. These latter two hrHPV DNA assays were validated in large randomized trials and cohorts with a follow-up ...
Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
screening rounds at a 3-year interval (n = 746). The GP5 +/6+- PCR EIA (EIA) was used as a comparator assay and showed sensitivities of 94.1% and 98.2% for CIN2 + and CIN3 +, respectively, with a clinical ...